Molecular Subtyping For Prognosis Evaluation In Resected Pancreatic Adenocarcinoma

Study Overview

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

N/A

Pancreatic Cancer Resectable

DEVICE: Multigene panel for next-generation sequencing

M-Cli200633-PC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2022-07-29	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2022-07-31
First Submitted that Met QC Criteria 2022-07-31	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2022-08-02
First Posted (ACTUAL) 2022-08-02	Results First Posted N/A	Last Verified 2022-07

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Disease-free survival (DFS)	Comparison of DFS between patients with specific HLA-I genotypes or not	2 years

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
34 Years

Accepts Healthy Volunteers:

Radically resected pancreatic adenocarcinoma (stage I-III)
Resected tumor tissues and matched blood cells available
Signed informed consent

Pancreatic cancer except pancreatic adenocarcinoma
Non-radical resection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

GeneCast Biotechnology Co., Ltd.

Investigators

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Wen C, Zhang L, Yang Y, Jin Y, Ren D, Zhang Z, Zou S, Li F, Sun H, Jin J, Lu X, Xie J, Cheng D, Xu Z, Chen H, Mao B, Zhang J, Wang J, Deng X, Peng C, Li H, Jiang C, Lin L, Zhang H, Chen H, Shen B, Zhan Q. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1941-1952. doi: 10.1097/JS9.0000000000000264.

Learn

Resources

PatientS

Caregivers

Clinical Trial Record